Prevalence of genital psoriasis in patients with psoriasis

Meeuwis, K.A.P.; Bleakman, Alison Potts; Kerkhof, P.C.M. van de; Dutronc, Yves; Henneges, Carsten; Kornberg, Lori; Menter, Alan

doi:10.1080/09546634.2018.1453125

Cited by 56 publications

(44 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although genital psoriasis is a common manifestation of plaque psoriasis associated with reduced quality of life and sexual health (2,3,7), it is frequently overlooked in clinical practice (7)(8)(9), and there have been few clinical studies evaluating therapies for genital psoriasis (4,14,(16)(17)(18). Hence, well-established treatment options for genital psoriasis are limited and awareness among both healthcare providers and patients is limited.…”

Section: Discussionmentioning

confidence: 99%

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Guenther¹,

Bleakman²,

Weisman³

et al. 2020

Acta Derm Venerol

View full text Add to dashboard Cite

Genital skin is commonly affected among patients with psoriasis. Genital psoriasis can cause problems such as genital itch and pain, and have negative effects on mental, social, and sexual health. Ixekizumab, can provide significant relief of genital psoriasis within 12 weeks of starting treatment. This study showed that patients with genital psoriasis continue to have symptom relief after one year of treatment with ixekizumab. Ixekizumab was efficacious in treating moderate-tosevere genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo through Week 12, then received 80 mg open-label ixekizumab every 4 weeks through Week 52. In patients initially randomized to ixekizumab, clear or almost clear genital skin was achieved for 73% of patients at Week 12 and 75% at Week 52. Persistent improvements were also observed for overall psoriasis, genital itch, and the impact of genital psoriasis on the frequency of sexual activity. The safety profile was consistent with studies of ixekizumab in patients with moderate-to-severe plaque psoriasis. Ixekizumab provided rapid and persistent improvements in the signs and symptoms of genital psoriasis for up to 52 weeks of treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Guenther¹,

Bleakman²,

Weisman³

et al. 2020

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…The lifetime incidence of nail disease in patients with psoriasis is estimated between 80 to 90% [16]. Between 29 and 63% of patients with psoriasis are impacted by psoriasis lesions in the genital area at some point during the course of the disease [17][18][19][20][21]. Collectively, these areas are considered to be hard-to-treat locations [22].…”

Section: Introductionmentioning

confidence: 99%

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort

et al. 2020

View full text Add to dashboard Cite

Background: Having psoriasis in hard-to-treat areas, i.e. the scalp, face, palms, soles, nails, and genitals, respectively, can impair patients' quality of life. We investigated the prevalence of hard-to-treat body locations of psoriasis, and described patients' clinical and demographic characteristics, and quality of life impacts in a population-based cohort. Methods: We performed a cross-sectional study using a total of 4016 adults (≥18 years) with psoriasis from the Danish Skin Cohort. Groups were compared to patients without involvement of hard-to-treat areas. Results: The most frequently affected hard-to-treat area was the scalp (43.0%), followed by the face (29.9%), nails (24.5%), soles (15.6%), genitals (14.1%), and palms (13.7%), respectively. Higher prevalence was generally seen with increasing psoriasis severity. Among all patients 64.8, 42.4, and 21.9% of patients had involvement of ≥1, ≥2, or ≥ 3 hard-to-treat areas. Those with involvement of certain hard-to-treat areas such as hands, feet, and genitals had clinically relevant DLQI impairments. Having involvement of one hard-to-treat area was significantly associated with other hard-to-treat areas affected even after adjusting for age, sex, and psoriasis severity. Conclusion: Psoriasis commonly affects hard-to-treat locations, even in patients with mild disease. For some of these areas, patient-reported disease burden, e.g. as measured by DLQI, is impaired.

show abstract

“…Lesions result in discomfort, embarrassment and impairment of psychosocial and sexual well‐being . Prevalence at the time of genital examination varies widely from 12% to 38% according to studies, probably as a result of the different prevalence evaluation methods. Moreover, prevalence is probably underestimated because of the reluctance of both patients and doctors to discuss genital involvement and genital QoL.…”

mentioning

confidence: 99%

GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis

Larsabal

Ly²,

Sbidian³

et al. 2018

Br J Dermatol

View full text Add to dashboard Cite

show abstract

Prevalence of genital psoriasis in patients with psoriasis

Abstract: A substantial proportion of patients experience genital lesions at some time during the course of psoriasis. Increased awareness of GenPs prevalence may drive improved assessment and treatment.

Cited by 56 publications

References 19 publications

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort

GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis

Contact Info

Product

Resources

About